NASDAQ$BDTX
Black Diamond Therapeutics I · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Black Diamond Therapeutics' financial results reported for Q3 2021 and provided a corporate update.
Black Diamond Therapeutics reported $235.0 million in cash, cash equivalents, and investments as of September 30, 2021. Net cash used in operations was $26.5 million for the third quarter of 2021. Research and development expenses were $27.6 million, and general and administrative expenses were $7.7 million for the third quarter of 2021.
- Black Diamond is preparing to initiate the Phase 2 portion of the MasterKey-01 study of BDTX-189 this year.
- Pre-clinical data from BDTX-1535, BRAF, and FGFR programs were presented at the AACR-NCI-EORTC (ANE) International Conference.
- A strategic partnership was established with OpenEye to accelerate drug discovery efforts through cloud-based molecular dynamics technology.
- The company's cash, cash equivalents, and investments of $235.0 million as of September 30, 2021, are expected to be sufficient to fund operations into the second half of 2023.
Headline financials
Revenue & EPS history
Black Diamond Therapeutics · Revenue · Quarterly
$0
Forward guidance
Black Diamond Therapeutics is focused on advancing its pipeline of MasterKey inhibitor programs, including BDTX-189, BDTX-1535, and BRAF and FGFR programs. The company expects to file an IND application for BDTX-1535 by the first half of 2022 and anticipates IND filings for both BRAF and FGFR programs in 2022.
Tailwinds
- The company remains on track with preparations for initiating the Phase 2 portion of the MasterKey-01 Phase 1/2 study of BDTX-189 by the end of 2021.
- Black Diamond continues to advance BDTX-1535 through IND-enabling studies and expects to file an IND application by the first half of 2022.
- The company continues to progress its early-stage pipeline programs designed to target cancers driven by mutations in BRAF and FGFR.
- Black Diamond anticipates IND filings for both BRAF and FGFR programs in 2022.
- The company's cash, cash equivalents, and investments of $235.0 million as of September 30, 2021, are expected to be sufficient to fund operations into the second half of 2023.
Headwinds
- The success, cost, and timing of the Company’s product candidate development activities and planned IND-enabling studies and clinical trials are subject to risks and uncertainties.
- The Company’s ability to execute on its strategy is subject to risks and uncertainties.
- Regulatory developments in the United States could impact the company's plans.
- The Company’s ability to fund operations is subject to risks and uncertainties.
- The impact that the ongoing COVID-19 pandemic will have on the Company’s clinical trials and pre-clinical studies, supply chain, and operations is uncertain.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2021
-1.4%
Avg return
Earnings day
-0.1%
Avg return
5 days after
-1.6%
Avg return
30 days after
40%
10 / 25 earnings
Positive
+15.6%
Q4 2019
Best reaction
-19.6%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -3.5% | +0.0% | -30.5% | |
| Q4 2025 | +2.4% | -3.7% | +33.3% | |
| Q3 2025 | -8.1% | -1.5% | -31.4% | |
| Q1 2025 | +2.1% | +5.2% | +19.7% | |
| Q4 2024 | -1.8% | +4.1% | -15.8% | |
| Q3 2024 | +10.0% | +10.0% | -21.4% | |
| Q2 2024 | -14.0% | -12.5% | +5.3% | |
| Q1 2024 | -12.0% | -17.3% | -25.2% | |
| Q4 2023 | +4.8% | +19.7% | +39.3% | |
| Q3 2023 | -4.2% | -6.3% | +24.7% | |
| Q2 2023 | -3.5% | -9.7% | +2.3% | |
| Q1 2023 | -2.1% | -1.6% | +11.5% | |
| Q4 2022 | -19.6% | +3.6% | -3.0% | |
| Q3 2022 | -2.7% | +13.6% | -28.1% | |
| Q2 2022 | +4.5% | +4.3% | -21.8% | |
| Q1 2022 | -9.4% | -8.4% | +5.4% | |
| Q4 2021 | +8.2% | +7.8% | +16.4% | |
| Q3 2021 | +2.0% | -4.0% | -22.8% | |
| Q2 2021 | -1.8% | -1.3% | +4.3% | |
| Q1 2021 | -4.0% | +9.0% | -50.3% | |
| Q4 2020 | +2.1% | +0.7% | +19.0% | |
| Q3 2020 | +9.2% | +3.2% | +8.1% | |
| Q2 2020 | -9.2% | -11.4% | -11.6% | |
| Q1 2020 | -1.1% | -5.4% | -19.5% | |
| Q4 2019 | +15.6% | +0.4% | +51.7% | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro